Highlights Theratechnologies Inc.

Equities

TH

CA88338H7040

Market Closed - Toronto S.E. Other stock markets 20:59:59 07/05/2024 BST			5-day change	1st Jan Change
1.7 ^CAD	0.00%		-3.95%	-20.56%

04-10	Update On Theratechnologies; Down More Than 5% On TSX As Q1 Net Loss Narrows, Awaits FDA Decision	MT
04-10	Theratechnologies Up Near 6% In US Premarket As Q1 Net Loss Narrows, Accelerates Phase 1 Trial of Ovarian Cancer Drug	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Update On Theratechnologies; Down More Than 5% On TSX As Q1 Net Loss Narrows, Awaits FDA Decision	04-10	MT
Theratechnologies Up Near 6% In US Premarket As Q1 Net Loss Narrows, Accelerates Phase 1 Trial of Ovarian Cancer Drug	04-10	MT
Theratechnologies Inc. Reports Earnings Results for the First Quarter Ended February 29, 2024	04-10	CI
Theratechnologies Brief: Citing Acceleration of Phase 1 trial of sudocetaxel zendusortide in advanced ovarian cancer with enrollment of next cohort of patients underway at higher dose level	04-10	MT
Theratechnologies Brief: FY2024 revenue guidance confirmed between US$87-$90 million and an Adjusted EBITDA in the range of $13-15 million	04-10	MT
Theratechnologies Brief: Q1 2024 consolidated revenue of US$16.2 Million; Says Report marks third consecutive quarter of near-flat-to-positive Adjusted EBITDA	04-10	MT
Theratechnologies Inc. Re-Affirms Earnings Guidance for the Fiscal Year 2024	04-10	CI
Theratechnologies Inc. Preclinical Data Presentation At AACR 2024 Highlights Versatility and Flexibility of SORT1+ Technology? Oncology Platform	04-08	CI
Theratechnologies To Present Preclinical Data at AACR on Multiple PDCs Showcasing Potential of SORT1+Technology Platform	03-28	MT
Theratechnologies Brief: To Present Preclinical Data at AACR on Multiple PDCs Showcasing Potential of SORT1+Technology Platform	03-28	MT
Theratechnologies Inc. Announces That It Will Phase Down Its Preclinical Oncology Research Activities	03-22	CI
Theratechnologies to Phase Down Preclinical Oncology Research Program	03-22	MT
Theratechnologies to Wind Down Preclinical Research, Focus on Ovarian Cancer Study	03-22	MT
Theratechnologies Initiates Higher Dose Level in Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer	03-21	MT
Theratechnologies Inc. Initiates Increased Dose Level in Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer	03-21	CI
Theratechnologies Down 30% In US Premarket -- Receives Refusal To File Letter From FDA	02-27	MT
Theratechnologies Shares Sink Premarket After FDA Refusal to File Letter	02-27	DJ
Theratechnologies Brief: Down 21% In US Premarket As Says Received Refusal To File Letter For Trogarzo Intramuscular Method Of Administration SBLA From FDA	02-27	MT
Theratechnologies Inc. Receives Refusal to File Letter for Trogarzo Intramuscular Method of Administration sBLA from FDA	02-27	CI
Theratechnologies Reports Record Quarterly Revenue of US$23.5 Million, Q4 Net Loss of $0.08 Per Share	02-21	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Theratechnologies Inc.

Equities

TH

CA88338H7040

Highlights

Filters